Primary Site >> Stomach Cancer
Gene >> BRAF
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. PMID: 14513361 Ref: BRAF and KRAS mutations in stomach cancer. PMID: 14534542 Ref: BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. PMID: 14668801 |
Ref: Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability. PMID: 14618633 Ref: Rapid detection of mutations in the BRAF gene using real-time polymerase chain reaction and melting curve analysis. PMID: 15104286 Ref: BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. PMID: 15613458 Ref: BRAF/K-ras mutation, microsatellite instability, and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas. PMID: 15616773 |
Ref: Mutational analysis of the ARAF gene in human cancers. PMID: 15676015 Ref: CGMIM: automated text-mining of Online Mendelian Inheritance in Man (OMIM) to identify genetically-associated cancers and candidate genes. PMID: 15796777 Ref: The prevalence of PIK3CA mutations in gastric and colon cancer. PMID: 15994075 Ref: Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. PMID: 16007118 Ref: No association between EGF gene polymorphism and gastric cancer. PMID: 16214932 Ref: ERBB2 kinase domain mutation in a gastric cancer metastasis. PMID: 16309427 |
Ref: Somatic mutations of the ERBB4 kinase domain in human cancers. PMID: 16187281 Ref: Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. PMID: 16397024 Ref: Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. PMID: 17047397 |
Ref: Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. PMID: 17693665 |
Ref: Down-regulation of epidermal growth factor receptor by selective expansion of a 5'-end regulatory dinucleotide repeat in colon cancer with microsatellite instability. PMID: 19584170 Ref: Genetic and epigenetic characteristics of gastric cancers with JC virus T-antigen. PMID: 19938198 |
Ref: Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. PMID: 20526349 |
Ref: Oncogenic mutations in gastric cancer with microsatellite instability. PMID: 20937558 Ref: Discovery of a novel B-Raf fusion protein related to c-Met drug resistance. PMID: 21936566 Ref: Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). PMID: 22152101 |
Ref: In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. PMID: 22011788 Ref: A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation. PMID: 22745804 Ref: Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. PMID: 22935382 |
Ref: ARMS-PCR for detection of BRAF V600E hotspot mutation in comparison with Real-Time PCR-based techniques. PMID: 23460942 Ref: KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. PMID: 23511561 Ref: Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification. PMID: 23819947 Ref: Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine. PMID: 23846438 Ref: Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway. PMID: 23911227 Ref: The utility of immunohistochemistry for providing genetic information on tumors. PMID: 24065374 Ref: HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. PMID: 24146218 Ref: Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. PMID: 24196786 Ref: BRAF mutation in multiple primary cancer with colorectal cancer and stomach cancer. PMID: 24759670 |
Ref: Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. PMID: 24122810 Ref: SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review. PMID: 24503755 Ref: DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach. PMID: 24674026 Ref: Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. PMID: 24774510 Ref: DNA methylation accumulation and its predetermination of future cancer phenotypes. PMID: 24962701 |
Ref: [Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm]. PMID: 25372301 Ref: Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells. PMID: 25473895 Ref: Cetuximab-induced insulin-like growth factor receptor I activation mediates cetuximab resistance in gastric cancer cells. PMID: 25625229 Ref: Microsatellite instability: an update. PMID: 25701956 Ref: Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer. PMID: 25815786 Ref: Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies. PMID: 25882375 Ref: Cancer mutation screening: Comparison of high-resolution melt analysis between two platforms. PMID: 25932046 Ref: Increased expression of LncRNA BANCR is associated with clinical progression and poor prognosis in gastric cancer. PMID: 26054683 Ref: BRAF activated non-coding RNA (BANCR) promoting gastric cancer cells proliferation via regulation of NF-kappaB1. PMID: 26248136 Ref: Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer. PMID: 26567773 |
Ref: Effects of chitosan nanoparticle-mediated BRAF siRNA interference on invasion and metastasis of gastric cancer cells. PMID: 25794798 Ref: Clinicopathological and molecular alterations in early gastric cancers with the microsatellite instability-high phenotype. PMID: 26538087 Ref: HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. PMID: 26690310 Ref: Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. PMID: 26811494 Ref: Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model. PMID: 26837764 Ref: Braf, Kras and Helicobacter pylori epigenetic changes-associated chronic gastritis in Egyptian patients with and without gastric cancer. PMID: 27116958 Ref: [Clinicopathological characteristics of colorectal carcinoma in the elderly]. PMID: 27215512 Ref: Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. PMID: 27437872 Ref: Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside. PMID: 27792246 |
Ref: Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF. PMID: 28182330 Ref: Molecular Testing for Gastrointestinal Cancer. PMID: 28219002 Ref: Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer. PMID: 28314274 Ref: Erratum to: Braf, Kras and Helicobacter pylori epigenetic changes-associated chronic gastritis in Egyptian patients with and without gastric cancer. PMID: 28444545 Ref: Genomic Profiling of Small-Bowel Adenocarcinoma. PMID: 28617917 Ref: Distinct Involvement of the Sonic Hedgehog Signaling Pathway in Gastric Adenocarcinoma of Fundic Gland Type and Conventional Gastric Adenocarcinoma. PMID: 28738329 Ref: Gastric Medullary Carcinoma with Sporadic Mismatch Repair Deficiency and a TP53 R273C Mutation: An Unusual Case with Wild-Type BRAF. PMID: 28840050 Ref: BANCR: a cancer-related long non-coding RNA. PMID: 28979803 Ref: Hepatoid Adenocarcinoma of the Stomach: A Challenging Diagnostic and Therapeutic Disease through a Case Report and Review of the Literature. PMID: 29034239 |
Ref: Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes. PMID: 28873240 Ref: Molecular profiling and comprehensive genome-wide analysis of somatic copy number alterations in gastric intramucosal neoplasias based on microsatellite status. PMID: 29468422 Ref: The BRAF activated non-coding RNA: A pivotal long non-coding RNA in human malignancies. PMID: 29484737 Ref: Acquired JHDM1D-BRAF fusion confers resistance to FGFR inhibition in FGFR2- amplified gastric cancer. PMID: 30045926 Ref: HER2: An emerging target in colorectal cancer. PMID: 30100092 |